27. Immune reconstitution in children with HIV infection after Anti-retroviral (ARV) treatment
Main Article Content
Abstract
This is a cross-sectional study of 20 patients aged from 2.5 month-old to 12.5 years old diagnosed with HIV-1 infection and treated by anti-retroviral drugs (ARV) at Vietnam National Children’s Hospital from 2014 to 2017. The results show that the cell count of TCD4 lymphocytes in peripheral blood significantly increased at 12 months and 18 months after ARV treatment with p = 0.009 and p = 0.046, respectively. The percentage of TCD4 lymphocytes significantly increased at six months, 12 months, and 18 months after treatment with p = 0.009, p 0.046 and p < 0.001, respectively. The cell count of TCD4 lymphocyte subsets as Th1 significantly increased at 12 months, and Th2 significantly increased at six months, 12 months, and 18 months after treatment. Th17 cells are not significantly different. The cell count of TCD8 lymphocytes shows no significant difference. However, the percentage of activated TCD8 lymphocytes are significantly decreased after ARV treatment.
Article Details
Keywords
HIV-1, ARV, Immune Reconstitution, TCD4 lymphocyte, TCD8 lymphocyte, Vietnam National Children’s Hospital
References
2. AIDS.gov (2016). A timeline of HIV/AIDS.
3. UNAIDS (2016). Global AIDS update 2016.
4. WHO (2013). The use of antiretroviral drugs for treating and preventing HIVinfection. www.who.int/hiv/pub/guidelines.
5. Richard D. Moore, Richard E. Chaisson (1999). Natural history of HIV infection in the era of combination antiretroviral therapy. https://www.ncbi.nlm.nih.gov/pubmed/10513653.
6. J. Parathyras, S. Gebhardt, R. Hillermann-Rebello et al (2009), A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups, J Hum Genet, 54(5), 261-265.
7. X. Bi, A. Ishizaki, L. V. Nguyen et al. (2016). Impact of HIV Infection and Anti-Retroviral Therapy on the Immune Profile of and Microbial Translocation in HIV-Infected Children in Vietnam. Int J Mol Sci, 17(8).
8. S. Desmonde, F. Dicko, F. Koueta et al. (2014). Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. AIDS, 28(11), 1645-1655.
9. Miguel Goicoechea et al. Determinants of CD4+T Cell Recovery during Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV-1 DNA. https://www.ncbi.nlm.nih.gov/pubmed/16741879.
10. Daan W. Notermans. Immune Reconstitution after 2 Years of Successful Potent Antiretroviral Therapy in Previously Untreated Human Immunodeficiency Virus Type 1 - Infected Adults. https://www.ncbi.nlm.nih.gov/pubmed/10479130.
11. V. Sorrenti, B. Marenda, S. Fortinguerra et al (2016). Reference Values for a Panel of Cytokinergic and Regulatory Lymphocyte Subpopulations. Immune Netw, 16(6), 344-357.
12. P. W. Hunt, H. L. Cao, C. Muzoora et al (2011). Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS, 25(17), 2123-2131.
13. P. Ondoa, S. Koblavi-Deme, M. Y. Borget et al (2005). Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d’Ivoire. Clin Exp Immunol, 140(1), 138-148.
14. Bofill M Mocroft A, Lipman M et al. (1997). CD8+, CD38+lymphocyte percents: a useful immunological marker for monitoring HIV-1 infected patients. AIDS, 14:158–162.
15. Vanham G Kestens L, Gigase P et al (1992). Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS, 6: 793–797.